3417 related articles for article (PubMed ID: 15167950)
1. [Are all antihypertensive drugs renoprotective?].
Wolf S; Risler T
Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
[TBL] [Abstract][Full Text] [Related]
2. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
3. [Retrospective studies and prospects of therapy for hypertension].
Maisch B; Brilla C; Kruse T; Noll B; Bethge C
Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
[TBL] [Abstract][Full Text] [Related]
4. Current recommendations for the treatment of hypertension: are they still valid?
Moser M
J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
[TBL] [Abstract][Full Text] [Related]
5. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hypertension in chronic kidney disease.
Toto RD
Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
[TBL] [Abstract][Full Text] [Related]
8. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
9. Nephroprotection by antihypertensive agents.
Schmieder RE
J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S55-64. PubMed ID: 7898095
[TBL] [Abstract][Full Text] [Related]
10. The renoprotective effect of antihypertensive drugs.
Locatelli F; Del Vecchio L; Marai P; Colzani S
J Nephrol; 1998; 11(6):330-6. PubMed ID: 10048500
[TBL] [Abstract][Full Text] [Related]
11. Comparison of renin-angiotensin to calcium channel blockade in renal disease.
Tikkanen I; Johnston CI
Kidney Int Suppl; 1997 Dec; 63():S19-22. PubMed ID: 9407414
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive therapy in the presence of proteinuria.
Sarafidis PA; Khosla N; Bakris GL
Am J Kidney Dis; 2007 Jan; 49(1):12-26. PubMed ID: 17185142
[TBL] [Abstract][Full Text] [Related]
13. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
14. Choice of antihypertensive drug in the diabetic patient.
Ong HT; Cheah JS
MedGenMed; 2005 May; 7(2):74. PubMed ID: 16369452
[TBL] [Abstract][Full Text] [Related]
15. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
16. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
Ravera M; Deferrari L; Ratto E; Vettoretti S; Parodi D; Deferrari G
Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
Ruilope LM
Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
[TBL] [Abstract][Full Text] [Related]
18. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.
Fournier A; Oprisiu-Fournier R; Serot JM; Godefroy O; Achard JM; Faure S; Mazouz H; Temmar M; Albu A; Bordet R; Hanon O; Gueyffier F; Wang J; Black S; Sato N
Expert Rev Neurother; 2009 Sep; 9(9):1413-31. PubMed ID: 19769454
[TBL] [Abstract][Full Text] [Related]
19. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
[TBL] [Abstract][Full Text] [Related]
20. Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering?
Weir MR
Curr Opin Nephrol Hypertens; 2007 Sep; 16(5):416-21. PubMed ID: 17693755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
